{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:42:51Z","timestamp":1762659771780,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.taap.2019.03.024","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T14:39:19Z","timestamp":1553611159000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Validation of a multiplexed LC\u2013MS\/MS clinical assay to quantify insulin-like growth factor-binding proteins in human serum and its application in a clinical study"],"prefix":"10.1016","volume":"371","author":[{"given":"Nanjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Tengstrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Olaf","family":"Boernsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Bek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2019.03.024_bb0005","series-title":"Presented at the 57th ASMS Conference on Mass Spectrometry and Allied Topics","article-title":"Method development for absolute quantification of insulin growth factor binding proteins (IGFBP) in plasma samples by capillary LC\u2013MS","author":"Boernsen","year":"2009"},{"key":"10.1016\/j.taap.2019.03.024_bb0010","series-title":"Presented at the 58th ASMS Conference on Mass Spectrometry and Allied Topics","article-title":"Investigation of peptide loss in MRM-experiments during absolute protein quantitation. WP 108\/#179","author":"Boernsen","year":"2010"},{"key":"10.1016\/j.taap.2019.03.024_bb0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1530\/EJE-11-0923","article-title":"Functional and total IGFBP3 for the assessment of disorders of the GH\/IGF1 axis in children with chronic kidney disease, GH deficiency, or short stature after SGA status at birth","volume":"166","author":"B\u00fcscher","year":"2012","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.taap.2019.03.024_bb0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1074\/mcp.M113.036095","article-title":"Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach","volume":"13","author":"Carr","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.taap.2019.03.024_bb0025","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdt057","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer","volume":"24","author":"Cohn","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2019.03.024_bb0030","article-title":"Revisiting the IGF-1R as a breast cancer target","volume":"1","author":"Ekyalongo","year":"2017","journal-title":"Precision Oncol."},{"author":"EMA (European Medicines Agency)","key":"10.1016\/j.taap.2019.03.024_bb0035"},{"author":"FDA (U.S. Food and Drug Administration)","key":"10.1016\/j.taap.2019.03.024_bb0040"},{"key":"10.1016\/j.taap.2019.03.024_bb0045","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial","volume":"26","author":"Fuchs","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2019.03.024_bb0050","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1038\/jid.2013.287","article-title":"Enzyme immunoassay and enzyme-linked immunosorbent assay","volume":"133","author":"Gan","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.taap.2019.03.024_bb0055","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1038\/ctg.2016.49","article-title":"Identification of pathway-specific serum biomarkers of response to glucocorticoid and infliximab treatment in children with inflammatory bowel disease","volume":"7","author":"Heier","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"August","key":"10.1016\/j.taap.2019.03.024_bb0060","first-page":"37","article-title":"Multiplex immunoassays in clinical bioanalysis: the promise and challenges to implementation in clinical development","author":"Hidi","year":"2010","journal-title":"Life Sci. Tech. Bull."},{"issue":"6","key":"10.1016\/j.taap.2019.03.024_bb0065","first-page":"761","article-title":"The insulin-like growth factor-binding protein (IGFBP) superfamily","volume":"20","author":"Hwa","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.taap.2019.03.024_bb0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1677\/joe.0.1590297","article-title":"Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients","volume":"159","author":"Jehle","year":"1998","journal-title":"J. Endocrinol."},{"issue":"1","key":"10.1016\/j.taap.2019.03.024_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-014-9685-5","article-title":"Recommendations for validation of LC\u2013MS\/MS bioanalytical methods for protein biotherapeutics","volume":"17","author":"Jenkins","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.taap.2019.03.024_bb0080","series-title":"Handbook of LC\u2013MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations","article-title":"LC\u2013MS bioanalysis of endogenous compounds as biomarkers","author":"Jian","year":"2013"},{"key":"10.1016\/j.taap.2019.03.024_bb0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12031-015-0684-5","article-title":"Diagnostic clinical, electrodiagnostic and muscle pathology features of spinal and bulbar muscular atrophy","volume":"58","author":"Jokela","year":"2016","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.taap.2019.03.024_bb0090","first-page":"3","article-title":"Insulin-like growth factors and their binding proteins: biological actions","volume":"16","author":"Jones","year":"1995","journal-title":"Endocr. Rev."},{"issue":"19","key":"10.1016\/j.taap.2019.03.024_bb0095","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.4155\/bio.12.200","article-title":"Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules","volume":"4","author":"Jones","year":"2012","journal-title":"Bioanalysis"},{"issue":"11","key":"10.1016\/j.taap.2019.03.024_bb0100","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/JTO.0b013e3181ba2f1d","article-title":"Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751, 871) in combination with paclitaxel and carboplatin","volume":"4","author":"Karp","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.taap.2019.03.024_bb0105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/clinchem\/43.3.523","article-title":"Immunoassay of insulin-like growth factor binding protein-1","volume":"43","author":"Khosravi","year":"1997","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.taap.2019.03.024_bb0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/157489212798357930","article-title":"Insulin-like growth factor: current concepts and new developments in cancer therapy","volume":"7","author":"King","year":"2012","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"4","key":"10.1016\/j.taap.2019.03.024_bb0115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrd2006","article-title":"Multiplexed protein measurement: technologies and applications of protein and antibody arrays","volume":"5","author":"Kingsmore","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2019.03.024_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jchromb.2015.10.001","article-title":"Development, validation, and comparison of four methods to simultaneously quantify L-arginine, citruline, and ornithine in human plasma using hydrophilic interaction liquid chromatography and electrospray tandem mass spectrometry","volume":"1005","author":"Lai","year":"2015","journal-title":"J. Chromatogr. B"},{"issue":"87","key":"10.1016\/j.taap.2019.03.024_bb0125","article-title":"Alterations of circulating insulin-like growth factor system components and androgen insensitivity in patients with Kennedy's disease","volume":"112","author":"Manfras","year":"2004","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"1","key":"10.1016\/j.taap.2019.03.024_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/endo.131.1.1377122","article-title":"Not all insulin-like growth factor-binding proteins (IGFBPs) are detectable by western ligand blotting: case studies of PC12 pheochromacytoma and rat anterior pituitary IGFBPs and proteolyzed IGFBP-3","volume":"131","author":"Ocrant","year":"1992","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.taap.2019.03.024_bb0135","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0022-3476(96)70012-4","article-title":"Assays for insulin-like growth factors and their binding proteins: practicalities and pitfalls","volume":"128","author":"Rosenfeld","year":"1996","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.taap.2019.03.024_bb0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly","volume":"53","author":"Schmid","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.taap.2019.03.024_bb0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpba.2016.06.017","article-title":"Quantitative analysis of endogenous compounds","volume":"128","author":"Thakare","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"S4","key":"10.1016\/j.taap.2019.03.024_bb0155","first-page":"1","article-title":"LC\u2013MS\/MS bioanalysis method development, validation, and sample analysis: points to consider when conducting nonclinical and clinical studies in accordance with current regulatory guidances","author":"Whitmire","year":"2011","journal-title":"J. Anal. Bioanal. Tech."},{"key":"10.1016\/j.taap.2019.03.024_bb0160","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.leu.2403672","article-title":"High IGFBP-3 levels in marrow plasma in early stage MDS: effects on apoptosis and hemopoiesis","volume":"19","author":"Wilson","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.taap.2019.03.024_bb0165","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.006593","article-title":"Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry","volume":"10","author":"Zhang","year":"2011","journal-title":"Mol. Cell. Proteomics"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19301140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19301140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:46:39Z","timestamp":1758573999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X19301140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":32,"alternative-id":["S0041008X19301140"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2019.03.024","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a multiplexed LC\u2013MS\/MS clinical assay to quantify insulin-like growth factor-binding proteins in human serum and its application in a clinical study","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2019.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}